Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch workouts aim to beat Post-Chemo fatigue

NCT ID NCT07429487

Symptom relief Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either the exercise program or standard follow-up. The main goals are to see how well people stick with the exercise plan and whether it improves fatigue and quality of life after 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 98 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18 to 75 years old, 2. Histologically proven non-metastatic adenocarcinoma of breast, colorectal, ovarian, pancreatic, biliary, or gastric origin, 3. Adjuvant chemotherapy completed less than 3 months ago (excluding hormone therapy), 4. PS 0 or 1 according to the World Health Organization (WHO) scale, 5. No recurrence since the end of adjuvant chemotherapy, 6. Patient who has voluntarily agreed to participate in the study and sign the written informed consent form, 7. Patient affiliated with a Social Security scheme. Exclusion Criteria: 1. New cancer treatment planned (excluding hormone therapy), 2. Patient who has received adjuvant immunotherapy, 3. Cardiological contraindication to the program 4. Decompensated or unstable chronic conditions 5. Severe malnutrition 6. Rheumatological unfitness as determined by the oncologist, 7. Chronic respiratory failure requiring long-term O2 therapy 8. Diabetes with plantar ulceration 9. Progressive or chronic non-healing bedsore/wound 10. Recent unhealed fracture 11. Patient participating in another interventional clinical study at the time of signing the informed consent form. 12. Vulnerable persons as defined in Articles L1121-5 to -8

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bile duct adenocarcinoma breast adenocarcinoma breast cancer breast neoplasm colorectal adenocarcinoma colorectal cancer colorectal neoplasm Fatigue gastric adenocarcinoma malignant pancreatic neoplasm ovarian adenocarcinoma pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colorectal cancer Gastric adenocarcinoma Ovarian adenocarcinoma Pancreatic cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    RECRUITING

    Nice, 06100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.